Lumera Adds Two Biotech Luminaries to its Scientific Advisory Board; Scientists to Provide Strategic Direction for Bioscience Business Unit
"The addition of these two noted scientists to our Scientific Advisory Board is a tremendous gain for our Bioscience Business Unit. Their insight will be invaluable in moving forward with our strategic direction," said Dr. Timothy Londergan, Lumera's director, Bioscience Business Unit.
“The addition of these two noted scientists to our Scientific Advisory Board is a tremendous gain for our Bioscience Business Unit. Their insight will be invaluable in moving forward with our strategic direction”
Leroy Hood, M.D., Ph.D. is recognized as one of the world's leading scientists in molecular biotechnology and genomics, holding numerous patents and awards for his scientific breakthroughs. Dr. Hood earned an M.D. from Johns Hopkins University in 1964 and a Ph.D. in biochemistry from the California Institute of Technology in 1968. Since then, his research has focused on the study of molecular immunology and biotechnology. He has published more than 600 peer-reviewed papers and co-authored textbooks in biochemistry, immunology, molecular biology and genetics.
His professional career began at Caltech, where he and colleagues pioneered four instruments, the DNA and protein synthesizers and sequencers that constitute the technological foundation for contemporary molecular biology. One of the instruments has revolutionized genomics by allowing the rapid automated sequencing of DNA. Dr. Hood also was one of the first advocates and is a key player in the Human Genome Project -- the quest to decipher the sequence of human DNA.
In 2000, Dr. Hood founded the Institute for Systems Biology in Seattle, Washington, to pioneer systems approaches to biology and medicine. He is president and director of this organization and continues with his interest in biology, medicine, technology development, and computational biology.
Dr. Hood has played a role in founding several biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, Rosetta, and MacroGenics. His numerous awards include the Kyoto Prize for Advanced Technology (2002).
Joshua LaBaer, M.D., Ph.D., is the founder and Director of the Institute of Proteomics at Harvard Medical School, and is a board certified oncologist in Massachusetts. He attended the University of California at Berkeley as an undergraduate and completed medical school and graduate school at the University of California, San Francisco, where he studied steroid regulation of DNA transcription and protein-DNA interactions.
He completed his clinical studies at the Brigham and Women's Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute in Boston. He also pursued research interests at the Massachusetts General Hospital in Boston in the areas of breast cancer, mammalian cell cycle regulation and cell cycle checkpoint genes.
Dr. LaBaer is the inventor of a new protein array technology called Nucleic Acid Programmable Protein Arrays (NAPPA). The NAPPA technology, first published in the July 2004 issue of the journal Science, provides a simple, cost-effective way to produce, as a single element of a microarray, freshly synthesized protein corresponding to any gene of known sequence.
He currently holds an academic appointment through the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. The author of numerous publications, Dr. LaBaer is also an associate editor of the Journal of Proteome Research, a member of the Scientific Advisory Committee for the Proteome Society and a founding member of the Human Proteome Organization.
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
About the Institute for Systems Biology
The Institute for Systems Biology (ISB) is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. ISB's goal is to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The driving force behind the innovative systems biology approach is the integration of biology, computation and technology. This approach allows scientists to analyze all of the elements in a system rather than one gene or protein at a time. For more information about the ISB, visit www.systemsbiology.org
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.